Discovery of small molecule inhibitors of liver X receptor for pediatric metabolic disorders by structure based...

Area of Science:

• Biochemistry and Pharmacology
• Computational Chemistry
• Pediatric Medicine

Background:

• Pediatric metabolic disorders, including dyslipidemia, are a growing health concern.
• Lipid metabolism regulation involves the Liver X Receptor (LXR), a potential therapeutic target.
• Effective treatments for pediatric metabolic disorders are urgently needed.

Purpose of the Study:

• To discover potential Liver X Receptor (LXR) inhibitors for pediatric metabolic disorders using in-silico approaches.
• To identify novel therapeutic agents for dyslipidemia and related conditions in children.
• To establish a computational framework for drug discovery targeting LXR in pediatric populations.

Main Methods:

• In-silico drug discovery combining molecular modeling, quantum chemical analysis, and molecular dynamics (MD) simulations.
• Molecular docking against the ChEMBL database to screen for LXR-binding compounds.
• Quantum chemical analysis (DFT) and 100 ns MD simulations to assess electronic properties and complex stability.
• ADMET predictions for pharmacokinetic and toxicity profiling.

Main Results:

• Screening identified potential LXR inhibitors with favorable electronic properties for receptor interaction.
• MD simulations confirmed the stability of protein-ligand complexes.
• Computational analyses indicated suitable pharmacokinetic and toxicity profiles for the identified compounds.
• A robust computational framework for LXR inhibitor discovery was established.

Conclusions:

• This study presents a computational strategy for identifying LXR inhibitors relevant to pediatric metabolic disorders.
• The identified compounds show promise but require experimental validation for therapeutic potential.
• The findings contribute to the development of novel treatments for childhood dyslipidemia and related metabolic diseases.